Innate Pharma SA issued last night a turnover of 1 million euros for its first quarter 2011, compared with 0.1 million for the same period in 2010.
The turnover of the first quarter of 2011 due to payment by Novo Nordisk A / S to achieve by 2201 a step HPI clinic in February 2011. Remember qu'IPH 2201 is a monoclonal antibody Innate Pharma licensed by Novo Nordisk A / S.
In its statement, the company said that its turnover is currently comprised of income of collaborative agreements and research payments, among others, based on the achievement of certain milestones in the development of its drug candidates. As such, it has no pattern and is therefore likely to vary considerably from one period to another.
On March 31, 2011, cash, cash equivalents and current financial instruments of the Company amounted to 30.4 million.
The turnover of the first quarter of 2011 due to payment by Novo Nordisk A / S to achieve by 2201 a step HPI clinic in February 2011. Remember qu'IPH 2201 is a monoclonal antibody Innate Pharma licensed by Novo Nordisk A / S.
In its statement, the company said that its turnover is currently comprised of income of collaborative agreements and research payments, among others, based on the achievement of certain milestones in the development of its drug candidates. As such, it has no pattern and is therefore likely to vary considerably from one period to another.
On March 31, 2011, cash, cash equivalents and current financial instruments of the Company amounted to 30.4 million.
没有评论:
发表评论